These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 25052122)

  • 1. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN; Clinard VB; Woodis CB
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT; Kao CJ; DeGregorio MW
    Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
    Simon J; Portman D; Mabey RG;
    Maturitas; 2014 Mar; 77(3):274-81. PubMed ID: 24411556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA; Komi JO;
    Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
    Portman DJ; Bachmann GA; Simon JA;
    Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of ospemifene in the breast.
    Berga SL
    Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
    DeGregorio MW; Zerbe RL; Wurz GT
    Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
    Pinkerton JV; Kagan R
    Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic evaluation of ospemifene.
    McCall JL; DeGregorio MW
    Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):773-9. PubMed ID: 20429673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
    Simon JA; Altomare C; Cort S; Jiang W; Pinkerton JV
    J Womens Health (Larchmt); 2018 Jan; 27(1):14-23. PubMed ID: 29064335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of ospemifene or lubricants on clinical signs of VVA.
    Constantine G; Graham S; Koltun WD; Kingsberg SA
    J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ospemifene in the treatment of vulvovaginal atrophy.
    Barnes KN; Pearce EF; Yancey AM; Forinash AB
    Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
    Pinkerton JV; Stanczyk FZ
    Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
    Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
    Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia.
    Eder SE
    Womens Health (Lond); 2014 Sep; 10(5):499-503. PubMed ID: 25335541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Li N; Zhang Y
    J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ospemifene efficacy and safety data in women with vulvovaginal atrophy.
    Pup LD; Sánchez-Borrego R
    Gynecol Endocrinol; 2020 Jul; 36(7):569-577. PubMed ID: 32329400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
    Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
    Reid RL; Black D; Derzko C; Portman D
    J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.